4772742
Last Update Posted: 2022-10-31
Recruiting has ended
All Genders accepted | 18 Years-75 Years |
193 Estimated Participants | No Expanded Access |
Interventional Study | Does not accept healthy volunteers |
Eptinezumab in Adults With Migraine and Medication Overuse Headache
This study evaluates the efficacy of eptinezumab to prevent migraine and headache in patients with the combined diagnosis of migraine and medication overuse headache
Patients planned for randomization: 91 patients in the eptinezumab 100 mg group and 91 patients in the placebo group.
The total study duration from the Screening Visit to the Safety Follow-up Visit is approximately 36 weeks and includes a Screening Period (28-30 days), a Placebo-controlled Period (12 weeks), an Open-Label Period (12 weeks) and a Safety Follow-up Period (8 weeks). Patient will receive investigational medicinal product (IMP) at the Baseline Visit with either eptinezumab or placebo by IV infusion and at week 12 visit.
Eligibility
Relevant conditions:
Migraine
Medication Overuse Headache
If you aren't sure if you meet the criteria above speak to your healthcare professional. Criteria may be updated but not reflected here, do not hesitate to contact the trial if you think are close to fitting criteria.
locations
Data sourced from ClinicalTrials.gov